SCHEMBL13660730

SCHEMBL13660730

CC(C)(C)NC(=O)c1cccc(CN2CCN(C(=O)c3ccc(NC(=O)NCC4CC4)cc3)CC2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.49
MAPT P10636 3/20 0.49
MAPK1 P28482 2/20 0.49
HTT P42858 2/20 0.49
ACKR3 P25106 7/20 0.45
HDAC3 O15379 2/20 0.44
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
HDAC9 Q9UKV0 2/20 0.44
HDAC5 Q9UQL6 2/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PRKAB2 O43741 1/20 0.44
PRKAG1 P54619 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1016969 0.95 PRKAB2 (0.46) TP53MAPTMAPK1HTTACKR3
SCHEMBL1020199 0.89 TP53 (0.51) TP53MAPTMAPK1HTTACKR3
SCHEMBL12954825 0.89 MEN1 (0.46) TP53MAPTMAPK1HTTACKR3
SCHEMBL1017763 0.88 HTT (0.55) TP53MAPTMAPK1HTTACKR3
SCHEMBL1020415 0.88 HTT (0.46) TP53MAPTMAPK1HTTACKR3
SCHEMBL1020212 0.87 TP53 (0.46) TP53MAPTMAPK1HTTACKR3
SCHEMBL1020459 0.87 PRKAB2 (0.47) TP53MAPTMAPK1HTTACKR3
SCHEMBL12954974 0.86 DRD2 (0.47) ACKR3KMT2A
SCHEMBL12955111 0.85 BCHE (0.51) MAPTMAPK1ACKR3MEN1KMT2A
Hydrochloric Acid SCHEMBL1074147 0.85 ACKR3 (0.46) ACKR3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314091-B2 N-benzyl,N'-arylcarbonylpiperazine derivatives MSD OSS B.V. (NL) 2012-11-20 US claimed
US-8314091-B2 N-benzyl,N'-arylcarbonylpiperazine derivatives MSD OSS B.V. (NL) 2012-11-20 US disclosed
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES N.V. ORGANON AND PHARMACOPEIA, INC. 2009-10-22 US disclosed
WO-2009024550-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. ORGANON (NL) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES NPC1L1, NPC1, ABCB11 TP53 4778/4885MAPT 3316/4885MAPK1 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.